Join the Oncology Voice Network. Join for Free
How to Start a Diversity Equity & Inclusion Program in Pharma
Provide 5 keywords for SEO search separated by commas

How to Start a Diversity Equity & Inclusion Program in Pharma


Share This Article


Summary

In this episode, Tara Gonzalez joins to discuss the intricacies of establishing Diversity, Equity, and Inclusion (DEI) programs within organizations. She shares insights from her background and outlines the challenges and strategies for initiating DEI initiatives. Tara emphasizes the importance of structuring DEI functions and engaging the entire company, while highlighting the role of external consultants in conducting needs assessments. The conversation covers best practices, the necessity of leadership buy-in, and the ongoing development of DEI efforts. Tara concludes with valuable advice for those looking to implement DEI programs, providing a comprehensive overview of this crucial topic.

This episode features Tara Gonzales, Vice President Medical Affairs discusses how to start a DEI program in Pharma
Tara shares….

👉 How she stood up a DEI program from scratch
👉 Why there is such a need for DEI programs
👉 What companies can expect as far as impact of a well run DEI program
👉 What it takes to build a positive culture in a company

Click for Source
Provide 5 keywords for SEO search separated by commas

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Leveraging Creativity to Break into Your First MSL Role
Partner Avatar MSL Talk: Tom Caravela, Alec McCarthy

Leveraging Creativity to Break into Your First MSL Role

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
OVN Avatar Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Explore OVN